




**Creutzfeldt-Jakob Disease**  
*Foundation, Inc.*

# Prion Disease Overview


# What is a prion?

- *protein* and *infectious*
- *-ion* (infectious, e.g. *virion*)
- No nucleic acid (e.g., DNA, RNA, “building blocks of life)
- Non-degradable by typical sterilization




PrP: prion protein  
 PrP<sup>C</sup>: normal prion protein (c=cellular)  
 PrP<sup>Sc</sup>: disease causing protein (Sc=scrapie)


(b)



# Neuropathology



H & E Staining  
(spongiform changes)



Immunohistochemistry  
(abnormal prion protein)

# Animals

- Scrapie: sheep & goat
- Bovine spongiform encephalopathy (BSE): cow
- Chronic wasting disease (CWD): deer, elk, moose, caribou

# Human Epidemiology

- 1-2 new cases per million individuals per year across the entire population (all ages)
- 1/6,000-10,000 US deaths per year
- OH=10.5 million people
  - 10.5 new cases/yr
  - ~2.5 cases living past one year
  - Would not be unusual to have 13 active cases in OH

# Human Etiologies

● Sporadic

● Genetic

● Acquired

Genetic CJD


Fatal familial insomnia

Gerstmann-Sträussler-Scheinker

Kuru


Iatrogenic CJD

Variant CJD






# Age at Onset



Adapted from: Appleby BS, *J Neuropsychiatry Clin Neurosci* 2007

## Survival Time in Sporadic Creutzfeldt-Jakob Disease (n=90)




SCHOOL OF MEDICINE

CASE WESTERN RESERVE  
UNIVERSITY

Adapted from: Appleby BS, *Arch Neurol* 2009

# sCJD Clinical Presentations



Adapted from Appleby BS *et al.*, *Arch Neurol* 2009

# Diagnosing Probable sCJD


At least two clinical signs with dementia:

1. Myoclonus (e.g., twitches)
2. Cerebellar or visual symptoms (e.g., “drunken” walking, incoordination, depth misperception)
3. Pyramidal or extrapyramidal symptoms (e.g., weakness, tremors, Parkinson’s disease like walking)
4. Akinetic mutism (lack of voluntary speech & movement)

At least one of the following:

1. Periodic sharp wave complexes on electroencephalogram (EEG) (looks at brain waves)
2. 14-3-3 in spinal fluid and disease duration < 2 years
3. Abnormal findings in basal ganglia or at least two cortical (e.g., outside) regions on specific sequences on brain MRI

# Electroencephalogram (EEG)




Periodic sharp wave complexes


70µV

# Brain MRI

basal ganglia



cortex



# Cerebrospinal Fluid Tests


Markers of brain cell damage:

1. 14-3-3: positive, negative, or ambiguous
2. Tau: result is a number (0-tens of thousands)

Disease specific test:

1. RT-QuIC: detects abnormal prion protein  
(very specific)

# Real-Time Quaking-Induced Conversion (RT-QuIC)





# RT-QuIC: Highly Specific for sCJD

	14-3-3	Tau	RT-QuIC
Sensitivity	81%	95%	95%
Specificity	43%	71%	100%

Sensitivity: How good is the test at detecting a disease?

Specificity: How sure are you that it is the disease you are trying to detect?

# NPDPSA vs Mayo CSF 14-3-3 Testing

- 14-3-3 is done differently
- Mayo: must order tau separately
- RT-QuIC only available via NPDPSA
- Will automatically be contacted regarding interest in autopsy program if positive


# sCJD Molecular Subtypes

- A. Polymorphism (differences in code) at position 129 of the prion protein gene (MM, MV, or VV)
  
- B. Prion protein type (differ by size/weight) (e.g., 1 or 2)

sCJD subtype=A+B (MM1, VV2, etc)

Subtypes vary in neuropathology and clinical characteristics.

# Genetic Prion Diseases



PrP<sup>c</sup>



PrP<sup>m</sup>




PrP<sup>Sc</sup>

Genetic  
Prion Disease



# Penetrance

The likelihood that you will become ill if you have the mutation



# Clinical Features of Genetic Prion Disease

- Genetic CJD (multiple different mutations, e.g. E200K)
  - Resembles classic sporadic CJD
- Fatal Familial Insomnia (D178N-129M mutation)
  - Insomnia
  - Neuropsychiatric symptoms (anxiety, hallucinations)
  - Dementia typically late in the illness
- Gerstmann-Straussler-Scheinker Syndrome (several mutations)
  - Cerebellar signs and symptoms early
  - Parkinsonian symptoms early
  - Dementia usually later in the illness
  - Longer duration (e.g., years)

# Acquired Prion Disease

- Kuru
- Iatrogenic CJD (iCJD)
- Variant CJD (vCJD)

# Kuru





# Iatrogenic CJD

**Table 2** Clinical features of iatrogenic Creutzfeldt–Jakob disease according to the mode and route of infection

Mode of infection	Agent entry into brain	Mean incubation period (range)	Clinical presentation
Corneal transplant	Optic nerve	18 and 320 mo	Dementia/cerebellar
Stereotactic EEG	Intracerebral	16 and 20 mo	Dementia/cerebellar
Neurosurgery	Intracerebral	17 mo (12–28 mo)	Visual/dementia/cerebellar
Dura mater graft	Cerebral surface	11 y (16 mo–23 y)	Cerebellar (visual/dementia)
Growth hormone	Hematogenous (?)	15 y (4–36 y)*	Cerebellar
Gonadotrophin	Hematogenous (?)	13 y (12–16 y)	Cerebellar
Blood transfusion	Hematogenous (?)	6.5 and 8 y <sup>†</sup>	Psychiatric

\* Median and range were 12 (4 to 22) years in France; 17 (8 to 27) years in the United Kingdom; and 21 (10 to 28) years in the United States. The case with the longest incubation period (36 years) occurred in a New Zealand patient (hormone prepared in the United States).

† The incubation period of a third case is unknown, as the transmission was discovered only by detection of the pathognomonic misfolded protein in spleen and lymph node at autopsy in a patient with neither neurologic symptoms nor brain pathology, who died from an unrelated disease 5 years after having received contaminated blood (i.e., in a preclinical or subclinical stage of Creutzfeldt–Jakob disease).

Two criteria for acquired prion disease\*:

- 1) Taken from central nervous system
- 2) Placed in central nervous system, injected into body, or ingested

\*Only vCJD is known to have been transmitted by blood transfusions

# vCJD Characteristics

- Young age at onset (~20s)
- Longer duration (> 1 year)
- Psychiatric and sensory symptoms at presentation
- Negative 14-3-3, unrevealing EEG
- Different brain MRI findings
- Tonsil biopsy


## VARIANT CJD CASES WORLDWIDE

COUNTRY	TOTAL NUMBER OF PRIMARY CASES (NUMBER ALIVE)	TOTAL NUMBER OF SECONDARY CASES: BLOOD TRANSFUSION (NUMBER ALIVE)	RESIDENCE IN UK > 6 MONTHS DURING PERIOD 1980-1996
UK	175 (0)	3 (0)	178 <sup>§</sup>
France	27 (0)	-	1
Republic of Ireland	4 (0)	-	2
Italy	3 (0)	-	0
USA	4† (0)	-	2
Canada	2 (0)	-	1
Saudi Arabia	1 (0)	-	0
Japan	1* (0)	-	0
Netherlands	3 (0)	-	0
Portugal	2 (0)	-	0
Spain	5 (0)	-	0
Taiwan	1 (0)	-	1

† The third US patient with vCJD was born and raised in Saudi Arabia and has lived permanently in the United States since late 2005. According to the US case-report, the patient was most likely infected as a child when living in Saudi Arabia. The completed investigation of the fourth US patient did not support the patient's having had extended travel to European countries, including the United Kingdom or travel to Saudi Arabia. It confirmed that the case was in a US citizen born outside the Americas and indicated that his infection occurred before he moved to the United States; the patient had resided in Kuwait, Russia and Lebanon (see <http://wwwnc.cdc.gov/eid/article/21/5/pdfs/14-2017.pdf>)

\* The case from Japan had resided in the UK for 24 days in the period 1980-1996.

**Figure 6 vCJD deaths by year with fitted quadratic and cubic trend lines**



**BSE  
1980's**




# Asymptomatic vCJD Carriers

- Survey of UK appendices
- 16/32,441 were prion positive
- No difference by birth cohort
- All codon 129 polymorphisms represented
- Estimated infection prevalence of 1:2000



- Nordfjella wild reindeer area
- Infected moose

Norwegian Sea



**Distribution of Chronic Wasting Disease in North America**

- CWD in free-ranging populations
- Known distribution prior to 2000 (free-ranging)
- CWD in captive facilities (depopulated)
- CWD in captive facilities (current)



National Wildlife Health Center  
Madison, Wisconsin  
Updated May, 2017

All locations are approximations based on best-available information

Thank you !  
Questions ?